| Quarterly Financials | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 141 | 138 | 137 | 93 | 120 | 110 | 105 | 131 | 95 | 196 | 164 | 180 | 134 | 171 | 169 | 251 | 185 | 207 | 228 | 231 | 252 | 230 | 226 | 241 |
| Expenses | 148 | 133 | 129 | 108 | 100 | 91 | 108 | 123 | 95 | 116 | 151 | 154 | 119 | 147 | 146 | 177 | 161 | 175 | 185 | 188 | 212 | 192 | 191 | 210 |
| EBITDA | -7 | 6 | 7 | -15 | 21 | 19 | -3 | 8 | 0 | 79 | 13 | 26 | 15 | 24 | 23 | 74 | 24 | 32 | 43 | 42 | 40 | 38 | 35 | 32 |
| Operating Profit % | -9 % | -1 % | 0 % | -23 % | 16 % | 17 % | -5 % | -3 % | -3 % | 9 % | 7 % | 13 % | 10 % | 11 % | 9 % | 16 % | 12 % | 12 % | 16 % | 13 % | 13 % | 14 % | 12 % | 12 % |
| Depreciation | 31 | 32 | 32 | 23 | 30 | 30 | 29 | 20 | 20 | 20 | 20 | 27 | 22 | 18 | 8 | 7 | 8 | 8 | 9 | 8 | 8 | 9 | 9 | 9 |
| Interest | 0 | 0 | 3 | 1 | 14 | 13 | 13 | 12 | 11 | 10 | 7 | 5 | 8 | 9 | 8 | 8 | 6 | 4 | 4 | 4 | 4 | 3 | 4 | 4 |
| Profit Before Tax | -39 | -26 | -28 | -39 | -23 | -24 | -45 | -25 | -31 | 49 | -14 | -6 | -14 | -3 | 7 | 59 | 11 | 20 | 30 | 30 | 28 | 26 | 23 | 19 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | -1 | 0 | 1 | 0 | 1 | -3 | -1 | -1 | 2 | -3 |
| Net Profit | -39 | -26 | -28 | -39 | -23 | -24 | -45 | -25 | -31 | 49 | -14 | -7 | -15 | -5 | 8 | 59 | 9 | 20 | 29 | 33 | 29 | 27 | 21 | 22 |
| EPS in ₹ | -4.32 | -2.93 | -3.11 | -9.52 | -5.55 | -5.98 | -10.96 | -6.06 | -7.57 | 12.10 | -3.40 | -1.61 | -3.68 | -1.32 | 1.86 | 14.49 | 1.85 | 4.30 | 6.18 | 6.81 | 5.79 | 5.37 | 4.10 | 4.40 |
Orchid Pharma
Orchid Pharma
699.95
-10.45
(-1.47%)
Market Cap
3,550.08 Cr
EPS
19.65
PE Ratio
36.13
Dividend Yield
0.00 %
Industry
Healthcare52 Week High
1,997.40
52 Week Low
603.80
PB Ratio
2.84
Debt to Equity
0.25
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from3 analysts
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,702.20 | #1 4,08,414.80 | 35.57 | #1 54,729.00 | 12.06 | #1 10,980 | -18.99 | 55.97 | |
6,584.00 | 1,74,784.51 | 80.22 | 9,712.00 | 0.89 | 2,191 | 23.05 | 40.37 | |
1,572.00 | 1,26,971.67 | 22.93 | 28,409.50 | 7.12 | 5,291 | 9.88 | 70.77 | |
3,622.90 | 1,21,969.00 | 63.65 | 11,539.40 | 6.99 | 1,911 | 19.91 | 72.46 | |
1,287.40 | 1,07,442.68 | #1 18.77 | 33,741.20 | 16.73 | 5,725 | 1.26 | 54.50 | |
2,541.60 | 1,04,899.14 | 61.83 | 12,744.20 | 19.57 | 2,007 | -10.91 | 52.39 | |
980.10 | 98,620.99 | 21.15 | 23,511.00 | 13.82 | 4,615 | -0.19 | 54.96 | |
1,960.50 | 89,535.15 | 27.44 | 22,909.50 | #1 19.94 | 3,306 | #1 112.49 | 53.75 | |
32,895.00 | 69,899.58 | 50.72 | 6,684.70 | 10.80 | 1,414 | 27.83 | 42.22 | |
1,127.00 | 65,456.34 | 18.86 | 31,378.10 | 17.55 | 3,366 | -0.50 | 47.15 |
Forecast
Actual
Growth Rate
Revenue Growth
24.06 %
Net Income Growth
72.28 %
Cash Flow Change
586.97 %
ROE
1.37 %
ROCE
-18.34 %
EBITDA Margin (Avg.)
10.70 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 4,061 | 3,862 | 3,256 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,554 | 1,688 |
| Fixed Assets | 1,795 | 1,637 | 1,497 | 1,386 | 1,256 | 858 | 670 | 584 | 573 | 620 | 713 |
| Current Assets | 1,278 | 1,251 | 675 | 679 | 768 | 569 | 550 | 398 | 501 | 791 | 807 |
| Capital Work in Progress | 282 | 280 | 288 | 272 | 278 | 26 | 7 | 10 | 47 | 31 | 65 |
| Investments | 0 | 0 | 1 | 1 | 1 | 0 | 15 | 46 | 44 | 46 | 326 |
| Other Assets | 1,985 | 1,945 | 1,470 | 1,467 | 1,542 | 576 | 544 | 472 | 561 | 857 | 0 |
| Total Liabilities | 4,061 | 3,862 | 3,256 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,554 | 1,688 |
| Current Liabilities | 1,123 | 1,338 | 1,510 | 2,013 | 2,346 | 175 | 142 | 241 | 372 | 260 | 286 |
| Non Current Liabilities | 2,609 | 2,475 | 2,212 | 1,905 | 1,436 | 519 | 442 | 222 | 165 | 124 | 135 |
| Total Equity | 329 | 49 | -467 | -792 | -704 | 766 | 653 | 647 | 689 | 1,170 | 1,267 |
| Reserve & Surplus | 244 | -40 | -556 | -881 | -793 | 725 | 544 | 538 | 579 | 1,050 | 1,217 |
| Share Capital | 85 | 89 | 89 | 89 | 89 | 41 | 41 | 41 | 41 | 51 | 51 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 367 | -76 | -240 | 15 | 57 | -2 | -74 | -11 | 18 | -19 |
| Investing Activities | 1,334 | -2 | -176 | -28 | 46 | 167 | 67 | 113 | -31 | -312 |
| Operating Activities | -369 | 212 | 401 | 9 | 12 | 81 | 24 | 93 | 18 | 126 |
| Financing Activities | -597 | -286 | -465 | 33 | -0 | -250 | -165 | -217 | 31 | 167 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 98.07 % | 90.00 % | 90.00 % | 90.00 % | 90.00 % | 89.96 % | 89.96 % | 89.96 % | 89.96 % | 72.40 % | 72.40 % | 69.84 % | 69.84 % | 69.84 % | 69.84 % | 69.84 % | 69.84 % | 69.84 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 4.14 % | 1.96 % | 1.42 % | 1.94 % | 2.53 % | 2.69 % | 1.40 % |
| DIIs | 1.00 % | 3.44 % | 3.35 % | 3.35 % | 2.97 % | 2.97 % | 2.98 % | 3.94 % | 2.62 % | 13.49 % | 9.88 % | 14.50 % | 17.73 % | 18.93 % | 18.29 % | 18.99 % | 20.10 % | 19.43 % |
| Government | 0.00 % | 0.00 % | 0.04 % | 0.04 % | 0.04 % | 0.04 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.58 % | 2.34 % | 2.72 % | 2.83 % | 3.34 % | 3.69 % | 3.61 % | 3.44 % | 3.38 % | 3.10 % | 3.85 % | 7.79 % | 7.44 % | 7.16 % | 7.59 % | 6.42 % | 5.11 % | 6.91 % |
| Others | 0.35 % | 4.22 % | 3.89 % | 3.79 % | 3.65 % | 3.34 % | 3.44 % | 2.66 % | 4.03 % | 11.02 % | 13.87 % | 3.74 % | 3.03 % | 2.65 % | 2.35 % | 2.22 % | 2.27 % | 2.43 % |
| No of Share Holders | 30,343 | 33,379 | 34,798 | 33,535 | 33,698 | 33,679 | 32,717 | 30,894 | 29,523 | 29,039 | 29,197 | 36,931 | 36,720 | 34,695 | 36,363 | 34,158 | 34,303 | 39,827 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 26 Jun 2025 |  Extraordinary General Meeting | NA | 26 Jun 2025 | 669.00 | 701.95 |
| 26 May 2025 |  Quarterly Result Announcement | NA | 26 May 2025 | 759.20 | 754.40 |
| 12 Feb 2025 | Quarterly Result Announcement | NA | 12 Feb 2025 | 1,457.50 | 1,245.55 |
| 11 Nov 2024 | Quarterly Result Announcement | NA | 11 Nov 2024 | 1,394.75 | 1,499.45 |
| 21 Aug 2024 |  Annual General Meeting | NA | 21 Aug 2024 | 1,147.85 | 1,398.00 |
| 26 Oct 2015 |  Change Of Name | NA | 26 Oct 2015 | 0.00 | 0.00 |
Announcements
Intimation For Execution Of Deed Of Hypothecation In Favour Of HDFC Bank Limited
Jul 17, 2025
Jul 17, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 14, 2025
Jul 14, 2025Intimation Related To The Scheme Of Amalgamation Of Dhanuka
Laboratories Limited (Amalgamating Company) With Orchid Pharma Limited (Amalgamated Company/Company) And Their Respective Shareholders And Creditors (The Scheme) Under Regulation 30 Of SEBI (LisJul 10, 2025
Jul 10, 2025Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJun 30, 2025
Jun 30, 2025Closure of Trading WindowJun 26, 2025
Jun 26, 2025Shareholder Meeting / Postal Ballot-Outcome of Court Convened MeetingJun 26, 2025
Jun 26, 2025Intimation Of Record Date For Voting Rights Of Shareholders W.R.T. The Meeting Of Equity Shareholders Of Orchid Pharma Limited ("Company"/ "Amalgamated Company") Convened Pursuant To The Order Passed By Honble National Company Law Tribunal For ConsideringJun 09, 2025
Jun 09, 2025Intimation Under Regulation 30 Of SEBI Listing Regulations- Honble National Company Law Tribunal Order To Dispose-Off Dispute On Lease Rentals With DBS Bank India Limited.Jun 06, 2025
Jun 06, 2025Disclosure Of Corporate Guarantee On Behalf Of Orchid Bio-Pharma Limited (Wholly Owned Subsidiary)Jun 03, 2025
Jun 03, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJun 02, 2025
Jun 02, 2025Intimation On Receipt Of EIR After The USFDA Inspection At The Plant Of The Company Situated At AlathurMay 29, 2025
May 29, 2025Board Comments On Fine Levied By The ExchangeMay 28, 2025
May 28, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 28, 2025
May 28, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 26, 2025
May 26, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 26, 2025
May 26, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 26, 2025
May 26, 2025Annual Audited Financial Results For The Quarter And F.Y. Ended On March 31 2025May 26, 2025
May 26, 2025Board Meeting Outcome for Outcome Of Board Meeting For Considering And Approving Annual Audited Financial Results For The Quarter And F.Y. Ended On March 31 2025May 26, 2025
May 26, 2025Notice Of Meeting Of Equity Shareholders And Unsecured Creditors Of Orchid Pharma Ltd Convened Pursuant To The Order Passed By Honble National Company Law TribunalMay 25, 2025
May 25, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 20, 2025
May 20, 2025Board Meeting Intimation for The Board Meeting Scheduled To Be Held On May 26 2025May 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 15, 2025
May 15, 2025Intimation Related To The Scheme Of Amalgamation Of Dhanuka Laboratories Limited (Amalgamating Company) With Orchid Pharma Limited (Company/ Amalgamated Company) And Their Respective Shareholders And Creditors (The Scheme) Under Regulation 30 Of SEBI (LisMay 13, 2025
May 13, 2025Intimation Under Regulation 30 Read With Schedule III Of SEBI Listing RegulationsMay 10, 2025
May 10, 2025Intimation On Scheme Of Amalgamation Of Dhanuka Laboratories Limited ("Amalgamating Company") With Orchid Pharma Limited ("Company"/ "Amalgamated Company") And Their Respective Shareholders And Creditors.May 03, 2025
May 03, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 11, 2025
Apr 11, 2025Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsApr 09, 2025
Apr 09, 2025Intimation Of Letter(S)/Emails Received From Stock Exchanges As Cautionary Under SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 29, 2025
Mar 29, 2025Closure of Trading WindowMar 27, 2025
Mar 27, 2025Intimation Under Regulation 30- Scheme Of Amalgamation Of Dhanuka Laboratories Limited (Amalgamating Company) With Orchid Pharma Limited (Company/ Amalgamated Company) And Their Respective Shareholders And CreditorsMar 10, 2025
Mar 10, 2025Announcement under Regulation 30 (LODR)-Credit RatingMar 07, 2025
Mar 07, 2025Disclosure Regarding The Order Passed By Goods And Service Tax DepartmentFeb 28, 2025
Feb 28, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 19, 2025
Feb 19, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 15, 2025
Feb 15, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 12, 2025
Feb 12, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 12, 2025
Feb 12, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportFeb 12, 2025
Feb 12, 2025Statement Of Deviation Or Variation For The Quarter-III Of F.Y.2024-25 Ended On December 31 2024.Feb 12, 2025
Feb 12, 2025Integrated Filing (Financial)Feb 12, 2025
Feb 12, 2025Announcement under Regulation 30 (LODR)-Investor PresentationFeb 12, 2025
Feb 12, 2025Outcome Of The Board Meeting Held For Inter Alia Consideration And Approval Of Unaudited Limited Reviewed Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended On DecembFeb 12, 2025
Feb 12, 2025Board Meeting Outcome for Outcome Of Board MeetingFeb 12, 2025
Feb 12, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 06, 2025
Feb 06, 2025Board Meeting Intimation for Intimation Of Board Meeting Scheduled To Be Held On February 12 2025Feb 06, 2025
Feb 06, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 13, 2025
Jan 13, 2025Closure of Trading WindowDec 30, 2024
Dec 30, 2024Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 15, 2024
Nov 15, 2024Newspaper Publication Of Unaudited Limited ReviewedFinancial Results (Standalone & Consolidated) For Quarter- II And Half Year Ended On September 30, 2024 Of Financial Year 2024-25Nov 12, 2024
Nov 12, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 11, 2024
Nov 11, 2024Technical Indicators
RSI(14)
Neutral 40.82
ATR(14)
Volatile 22.11
STOCH(9,6)
Oversold 18.18
STOCH RSI(14)
Oversold 0.00
MACD(12,26)
Bearish -2.92
ADX(14)
Weak Trend 11.63
UO(9)
Bearish 37.15
ROC(12)
Downtrend And Accelerating -3.93
WillR(14)
Neutral -74.68
Mutual Fund Holdings
UTI Value Fund Direct-Growth 
JM Flexicap Fund Direct Plan-Growth 
Bandhan Small Cap Fund Direct-Growth 
Bajaj Finserv Healthcare Fund Direct-Growth 
Motilal Oswal Nifty Microcap 250 Index Fund Direct - Growth 
Groww Nifty Total Market Index Fund Direct - Growth 
Angel One Nifty Total Market Index Fund Direct - Growth 
Kotak Multi Asset Allocation Fund Direct - Growth 
Invesco India Multicap Fund Direct-Growth 
ITI Pharma and Healthcare Fund Direct - Growth 
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
